Original Source(s)
Related Content
FDA expands gastroesophageal cancer options
Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.
August 25, 2026
-
2 min
FDA Approves New First-Line TNBC Regimen
Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.
June 26, 2026
-
3 min
Inflammatory signatures may distinguish dental caries
Combining IL-17 with TNF-alpha showed strong discrimination between carious lesions and healthy controls, but performance was more modest against gingival inflammation.
September 9, 2026
-
3 min
